Theravance Biopharma, Inc. (TBPH) delivered a return of 56.12% over the past year. Since TBPH does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Theravance Biopharma, Inc. one year ago would be worth $15,612 today, representing a gain of $5,612.

Theravance Biopharma, Inc. (TBPH) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For TBPH, the total return equals the price-only return.

Yes, Theravance Biopharma, Inc. (TBPH) outperformed the S&P 500 by 31.13 percentage points over the past year. TBPH delivered a total return of 56.12%, compared to the S&P 500's 24.99%. This 31.13pp alpha means investors in TBPH earned more than a passive S&P 500 index fund.

Theravance Biopharma, Inc. (TBPH) experienced a maximum drawdown of -34.57% over the past year, declining from its peak on 2026-01-22 to its trough on 2026-03-06. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Theravance Biopharma, Inc. (TBPH)'s long-term returns with dividends reinvested. Over 10 years, the total return is -27.5% (-3.2% CAGR) — $10,000 would have grown to $7,247. Over 20 years: -27.8% total return (-1.6% CAGR) — $10,000 → $7,221. Over 30 years: -27.8% total return (-1.1% CAGR) — $10,000 → $7,221. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Theravance Biopharma, Inc.'s best calendar year was 2025 with a total return of 101.6%. Its worst year was 2021 with a total return of -37.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 138.6 percentage points.